EC calls for joint effort to stop the unnecessary use of antibiotics

16 November 2018
europe_big

The European Commission yesterday released the results of a new Eurobarometer study on the public knowledge on antibiotics and overall trends in their use ahead of the 11th European Antibiotic Awareness Day.

The study shows that there has been a positive evolution in the use of antibiotics: 32% of people said they had taken antibiotics in the last 12 months, compared to 40% in the 2009 survey. However, many of these antibiotics were taken unnecessarily: 20% of antibiotics were taken for flu or a cold and 7% took them without a medical prescription. 66% of the respondents know that antibiotics are of no use against colds, and 43% are aware that antibiotics are ineffective against viruses. Over two thirds of people would like to have more information about antibiotics.

In reaction to these figures, and on the occasion of the European Antibiotic Awareness Day,Commissioner Vytenis Andriukaitis said: “This Eurobarometer shows that more effort is needed to raise awareness and knowledge on antimicrobials among fellow citizens. Moreover, the latest estimates of 33 000 deaths per year in Europe due to antimicrobial resistance must serve as a wake-up call to us all. Most of these deaths are avoidable by stopping the unnecessary use of antibiotics and through better diagnosis and prevention of infections in hospitals and communities. I call on everyone who has influence in the prevention and treatment of infection to redouble their efforts to combat the threat fromantimicrobial resistance. On top of raising awareness and improving knowledge, we must join forces and tackle antimicrobial resistance from the animal health and environmental perspectives, as well as the human health angle. In a few days, the Council will give its green light for a new European legislation on veterinary medicines and medicated feed, a major breakthrough in this field.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical